Buy Plavix (Clopidogrel) without a prescription. No hidden fees!
Plavix, one of the few anti-clotting drugs on the selling on the market today, could take a big hit to its $8.5 billion sales rate (2007) as the result of two recent revelations which are resulting in the FDA reviewing the drug’s labeling. We believe it is inevitable that the Food and Drug Administration will impose a more restrictive label which will substantially reduce the use of Plavix by as much as 30%.
The Losers: Plavix is prescribed to prevent blood clots and as the second most prescribed drug in the world (25 million prescriptions in 2007), Plavix is widely prescribed for patients that have experienced heart attack, stroke, or other cardiovascular events and who are believed to be at high risk for a recurrent event caused by a blood clot. However, approximately 30% of patients taking Plavix do not metabolize the medication because of genetic variation thus receiving little or no benefit.
The Winners: The winners are those companies that will benefit from giving millions of PCR (polymerase chain reaction) based tests mandated by the FDA to detect the genetic variations that renders Plavix ineffective. We believe Roche Molecular Diagnostics and indirectly, Affymetirix (AFFX) which supplies the test to Roche, will be the major recepient of the label change but other PCR companies will also benefit.
In the December 22, 2008 issue of the New England Journal of Medicine, there are two studies that strongly suggest that information from patients taking Plavix over a number of years found that individuals with a particular gene variation had higher rates of heart attack incidents, death and other cardiac-related events. The gene variant appears to minimize the function of an enzyme needed to activate the medicine. A third study in the British journal Lancet found that in patients under the age of 40 who had history had a heart attack, the risk of having a new heart attack or death was three times greater for those with the gene variation. Two of the studies suggested the medication was less effective in about 30% of the population that has the mutated gene from one parent, while one study indicated the drug is less effective in the 5% of the population that has the gene from both parents.